Rivaroxaban (ATC B01AF01)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)
Opportunity Score
Why this score?
Opportunity
5 / 100
Complexity
20 / 100
Risk factors
The only lot (Rivaroxaban) is cancelled. No new contracts will be concluded under this notice for that active ingredien...
No estimated value, award criteria, or detailed eligibility criteria. This makes it impossible to assess the value or c...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Weak opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Mar 2027
- Conclude non-exclusive discount agreements for finished medicinal products (Open House model).
- Only specified active ingredient: Rivaroxaban (ATC B01AF01) – but this lot is cancelled.
Show full summary
This is an Open House model (non-exclusive discount agreements under §130a Abs. 8 SGB V) for finished medicinal products. The only listed lot (Rivaroxaban) is being cancelled as of 30 September 2025, with no new contracts. The overall submission deadline is 1 February 2027, but electronic submission is not allowed (email submission mentioned in XML notice). No estimated value, award criteria, or detailed eligibility criteria are provided. The tender appears to be a correction of a previous notice.
Risks
The only lot (Rivaroxaban) is cancelled. No new contracts will be concluded under this notice for that active ingredien...
No estimated value, award criteria, or detailed eligibility criteria. This makes it impossible to assess the value or c...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Contractors must be able to supply finished medicinal products with specified active ingredients.
- Agreements are non-exclusive and follow the Open House model.
- Contracts can be terminated early if AOK Hessen conducts an exclusive tender for the same active ingredients.
Award Criteria
Lot 1
Buyer
Location
Bad Homburg, DEU
Website
Identifier
DE114110216
Activity
Health
Lots (1)
LOT-0001
Rivaroxaban (ATC B01AF01)
This lot is cancelled as of 30 September 2025. No contracts will be concluded. A new procedure will be published. Scope: pharmaceutical product Rivaroxaban.
Location
Duration
Category
Award Criteria
Award details
Das LOS wird zum 30.09.2025 aufgehoben. Es werden keine Verträge mehr geschlossen. Ein neues Verfahren wird veröffentlicht.
Value note
Show original TED data
Original TED description
Das LOS wird zum 30.09.2025 aufgehoben. Es werden keine Verträge mehr geschlossen. Ein neues Verfahren wird veröffentlicht.
Procurement Details
- Publication date
- 20 Aug 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 546345-2025
Documents (1)
Similar tenders
France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord
Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)
Romania – Street-cleaning and sweeping services – Acord cadru de prestare a serviciilor de delegare a activităților de măturat, spălat, stropit si întreținerea căilor publice și activități de curățare și transport al zăpezii de pe căile publice și menținerea în funcțiune a acestora pe timp de polei sau îngheț, pe timp de iarnă din cadrul serviciului de salubrizare a orașului Negrești Oaș
France – Insurance services – MARCHE DE SERVICES EN ASSURANCE
Spain – Building-cleaning services – Servicios de limpieza en Centros de Sevilla, Murcia y Galicia, de la Agencia Estatal Consejo Superior de Investigaciones Científicas.
Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).
Opportunity Score
Why this score?
Opportunity
5 / 100
Complexity
20 / 100
Risk factors
The only lot (Rivaroxaban) is cancelled. No new contracts will be concluded under this notice for that active ingredien...
No estimated value, award criteria, or detailed eligibility criteria. This makes it impossible to assess the value or c...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications